Max Healthcare Institute Limited has informed the Exchange about transcript of Earnings Call held on May 22, 2026
MAXHEALTH · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Max Healthcare reported Q4 FY26 results with network revenue of INR 2,664 crore (+10% YoY) and operating EBITDA of INR 682 crore (+8% YoY), marking the 22nd consecutive quarter of growth. The company commissioned over 20% additional brownfield capacity across Mohali, Nanavati (Mumbai), and Max Smart (Delhi), with full operationalization expected in 2-3 months. A significant development was the completion of Kalinga Hospital acquisition (250-bed, Bhubaneswar) marking entry into Eastern India, plus board approval for INR 1,400 crore investment in a 700-bed greenfield hospital at Shaheed Path, Lucknow. Management noted temporary margin pressure (EBITDA margin at 26.8% vs 27.2% YoY) due to higher Average Length of Stay during multi-location capacity rollout, expecting operating leverage to improve as beds ramp up. The CGHS rate revision provided a net benefit of INR 140 crore annually, partially offset by INR 200 crore annual impact from discontinuing high-value chemotherapy drugs.
The earnings call reflects solid operational execution with strong cash generation (INR 581 crore FCF in Q4), though near-term margin pressure is expected as new capacity ramps up. The strategic expansion into Eastern India and multi-location growth pipeline position the company for sustained long-term growth.